Diabetes Epidemiology and Management, published by Elsevier, is an innovative open-access journal that has been addressing the critical issues surrounding diabetes since its inception in 2021. This journal integrates a comprehensive exploration of the epidemiology, prevention, and management of diabetes, making it a pivotal resource within the fields of Endocrinology, Diabetes and Metabolism, and Internal Medicine. With a digital presence represented by E-ISSN 2666-9706, it currently holds a commendable position in the academic landscape, categorized in the Q3 quartile for both Endocrinology and Internal Medicine as per the 2023 metrics. The journal aims to enhance understanding and promote research on diabetes, offering authors a platform to share their findings with a global audience. Researchers, professionals, and students alike can benefit from this essential resource, which is dedicated to advancing the knowledge base and improving clinical practices in diabetes management. With open access options since 2021, the journal ensures that vital research is widely accessible, driving innovation and collaboration in the fight against diabetes.

Journal of Diabetes Investigation is a prestigious open-access journal published by WILEY, dedicated to advancing knowledge in the fields of Endocrinology, Diabetes, and Metabolism. With its ISSN 2040-1116 and E-ISSN 2040-1124, the journal provides a vital platform for researchers, healthcare professionals, and students to disseminate high-quality research, foster innovative ideas, and engage with cutting-edge developments in diabetes investigation. Since its inception in 2010, the journal has established a solid reputation, ranking in Q2 for Endocrinology and Diabetes and Metabolism, and Q1 for both Internal Medicine and Miscellaneous Medicine categories in 2023. Its Scopus rankings further underscore its impact, notably at the 76th percentile in Internal Medicine. The open access model, adopted in 2014, ensures that vital information is freely available, promoting global collaboration and knowledge sharing. The journal is not only a reflection of Australia's commitment to medical research but also a beacon for advancements that can ultimately enhance patient outcomes in diabetes care.

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, published by Springer, is a leading journal in the field of endocrinology, diabetes, and metabolism, with an impressive Q1 ranking in both categories as of 2023. With an ISSN of 1389-9155 and E-ISSN 1573-2606, this journal serves as a vital resource for researchers, clinicians, and students seeking comprehensive reviews that address the latest advancements and interdisciplinary approaches in the management of endocrine and metabolic disorders. Operating from the Netherlands, it features articles that are rigorously peer-reviewed and is notable for its significant impact factor reflected in its Scopus rankings, placing it in the top percentile of its categories. Although it does not currently offer open access, it provides critical insights applicable to both basic and clinical settings, making it indispensable for those dedicated to enhancing patient outcomes in endocrine health.

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES is a distinguished journal published by GEORG THIEME VERLAG KG, dedicated to advancing research and understanding in the fields of endocrinology, diabetes, and metabolism. With an ISSN of 0947-7349 and an E-ISSN of 1439-3646, this journal serves as a critical platform for disseminating high-quality research findings, reviews, and clinical studies from 1983 to 2024. The journal holds an impactful position within its respective categories, notably achieving Q3 in Endocrinology and Diabetes and Metabolism, and Q2 in Internal Medicine as per the 2023 category quartiles. Additionally, it ranks in the 57th and 46th percentiles in the Scopus rankings for Internal Medicine and Endocrinology, Diabetes and Metabolism, respectively. Though not an open-access publication, the journal caters to a global audience of researchers, professionals, and students, facilitating knowledge exchange and fostering collaboration within this vital area of medical science.

Revista Portuguesa de Endocrinologia Diabetes e Metabolismo is a pivotal journal dedicated to advancing the fields of endocrinology, diabetes, and metabolism. Published by the esteemed SOC PORTUGUESA ENDOCRINOLOGIA, DIABETES & METABOLISMO-SPEDM, this journal serves as a platform for the dissemination of high-quality research, clinical studies, and innovative practices within these related disciplines. With a commitment to providing insightful and impactful content, the journal aims to foster knowledge sharing among researchers, healthcare professionals, and students interested in the latest developments in endocrine disorders and metabolic diseases. Although currently not open access, the journal's comprehensive approach and rigorous peer-review process ensure that it remains a respected source of information for its readers in Portugal and beyond. With its address rooted in the heart of Lisbon, the Revista Portuguesa de Endocrinologia Diabetes e Metabolismo plays a vital role in enhancing the understanding and treatment of endocrine and metabolic conditions in the modern healthcare landscape.

The Journal of Diabetes, published by WILEY, is a premier Open Access platform since 2022, dedicated to advancing knowledge in the fields of endocrinology, diabetes, and metabolism. With an ISSN of 1753-0393 and an E-ISSN of 1753-0407, this journal provides a vital resource for researchers and practitioners looking to keep up with the latest findings and trends in diabetes management and treatment. As of 2023, it holds a commendable Q2 rating in its category and ranks #78 out of 244 in the Scopus classification, placing it in the 68th percentile, thus affirming its significance in the academic community. Covering a timeline from 2009 to 2024, the journal invites submissions that contribute to the understanding of diabetes pathophysiology, innovative therapies, and clinical practices, making it an essential read for anyone dedicated to improving patient outcomes in diabetes care.

Welcome to the Journal of the ASEAN Federation of Endocrine Societies, a pioneering publication dedicated to advancing knowledge and research in the fields of Endocrinology, Diabetes, and Metabolism. Established by the ASEAN Federation Endocrine Society and open access since 2011, this journal enhances the dissemination of critical findings and encourages collaboration among professionals and researchers across Southeast Asia and beyond. With an ISSN of 0857-1074 and E-ISSN of 2308-118X, the journal is indexed within Quartile 4 in the 2023 rankings of its categories, reflecting its commitment to providing a platform for scholarly work despite its emerging status. Situated in the Philippines, the journal focuses on the latest trends, treatments, and innovative research approaches in endocrinology, making it an essential resource for academics, clinicians, and students alike. We invite you to explore our content and contribute to advancing the endocrine sciences.

DIABETES OBESITY & METABOLISM, published by Wiley, is a premier international journal dedicated to the fields of endocrinology, diabetes, and metabolic disorders. With an impressive impact factor and its status as a Q1 journal in multiple categories—including Endocrinology and Internal Medicine—this publication is highly regarded in the academic community. Since its inception in 1999, the journal has served as a crucial platform for the dissemination of cutting-edge research, reviews, and clinical studies, driving advancements in understanding and treatment of diabetes and obesity. Researchers and professionals alike benefit from its rigorous peer-review process and extensive reach, as it aims to bridge the gap between laboratory findings and clinical applications. Although not an Open Access journal, articles are accessible through institutional subscriptions, ensuring that vital knowledge reaches those committed to enhancing patient care and expanding the scientific body of work in these pivotal areas.

DIABETES-METABOLISM RESEARCH AND REVIEWS, published by WILEY, is an esteemed academic journal focusing on the forefront of research in the fields of endocrinology, diabetes, and metabolism. Since its inception in 1999, this journal has become a crucial resource for researchers, professionals, and students, boasting an impressive impact factor that reflects its high citation rates and contribution to the field. With a 2023 classification of Q1 in several categories including Endocrinology and Internal Medicine, it ranks among the top journals globally, demonstrating its significant influence and authority. The journal serves as a platform for the dissemination of innovative research, reviews, and methodologies that advance understanding and treatment of metabolic disorders. By offering valuable insights and fostering collaboration within the scientific community, DIABETES-METABOLISM RESEARCH AND REVIEWS is essential reading for anyone involved in diabetes research and clinical practice.

Diabetes Mellitus, published by the Endocrinology Research Centre in the Russian Federation, is an esteemed open-access journal dedicated to the field of endocrinology, diabetes, and metabolism. Since its inception in 1998, this journal has been a pivotal platform for disseminating cutting-edge research and comprehensive reviews that address the multifaceted challenges posed by diabetes. With its current quartile ranking of Q4 in Endocrinology and the associated fields, as well as commendable involvement in the broader scope of Internal Medicine, Diabetes Mellitus plays a crucial role in enhancing clinical practices and informing innovative therapeutic strategies. The journal caters to a diverse audience of researchers, healthcare professionals, and students, particularly those seeking to expand their knowledge and improve patient outcomes in diabetes care. With a commitment to fostering scientific conversation and collaboration, Diabetes Mellitus is an invaluable resource for anyone engaged in the fight against diabetes and its complications.